Let's learn about CRC #Clinicaltrials Patients, caregivers, clinicians, patient advocates: All are welcome! Volunteer activity organized by @manjuggm
@crctrialschat.bsky.social
Joined May 2022
- Tweets4.4K
- Following1.1K
- Followers974
- Likes4.3K
Pinned Tweet
Everyone with #EarlyOnsetCRC wants to know why they were diagnosed with #colorectalcancer..
This month's #CRCTrialsChat #VideoShorts on the @CancerGrand #PROSPECT project explores this question
Let's hear from the PIs, Dr. @AndyChanMD & Dr. @yincaoScD! See you tomorrow!
#CRCSM
#CRCTrialsChat retweeted
@TheMSCCRT Excited to launch the #MS80By2030 #CRCScreening campaign focused on Mississippians ages 45-59. Because if we can get these folks screened, hopefully they will continue to stay screened!
@NCCRTnews #TowardsAHealthierMississippi
Too many Mississippians are dying from late‑stage colorectal cancer. The 80 by 2030 campaign aims to increase screening for adults ages 45 to 59 and save lives through early detection and prevention. Learn more: umc.edu/news/News_Articles/2…
#CRCTrialsChat retweeted
Call-on Congress is evolving, and global researchers are joining the fight against early-onset #colorectalcancer.
Learn what's changing, why it matters, and how advocates can help drive progress at our next Advocacy Action Hour. Register now at fightcrc.org/actionhrx
#CRCTrialsChat retweeted
#AACR26 Excited & honored to unveil initial results from the phase-2 CLOVER ☘️ trial.
CCR5-targeting
Leronlimab with
Oral chemotherapy &
VEGF-inhibitor
Enriched
Regimen
🏃♂️to our session
🔖 2-5PM
📍Section41🪧Poster14
👇🏽Promising #ctDNA💦📉
MSS #ColorectalCancer
@OncoAlert
#CRCTrialsChat retweeted
Thank you, @chadinabhan for having me on your pod.
Enjoyed talking all things GI rad onc with you!
What’s happ in the world of radiation onc when it comes to GI cancers?
A lot.
@NiuSanford joins #HealthcareUnfiltered podcast today and articulates nicely advances, controversies, and even if we can avoid RT in some cases. Streaming everywhere.
podcasts.apple.com/us/podcas…
#CRCTrialsChat retweeted
Huge congratulations to @waraonc23 and Dr. Takahashi on their presentations at the @AACR annual meeting.
Obesity shaping CRC biology + immune checkpoints, and consistent irAE rates with ICIs across populations—both highly relevant, impactful work.
Great working with them on these projects. More to come soon in publications.
@RoswellPark @RoswellHemOnc @Deebacca @MiamiCancerInst @BHCancerCare @BaptistHealthSF
#CRCTrialsChat retweeted
🙏@AACR for inviting me to talk re pt-centric approaches for oral therapies in CRC. Always happy to highlight our @UTMDAnderson CRC team using ctDNA & novel trial design to bring best & safest to our pts, led by the incredible @JarettFeldmanMD, @vserpashigbie & Dr Alisha Bent!
"The patient experience must always be considered when prescribing oral therapies." @VanMorrisMD from @UTMDAnderson describes self-administered cancer treatments for #colorectalcancer patients and predictors of poor adherence. @AACR AM 2026. #AACR26
#CRCTrialsChat retweeted
Drug development is supposed to be linear.
Build the drug → use the drug → resistance shows up → then figure out what to do next.
Aaaand not what Revolution Medicines is doing. 🧬
At #AACR26 they disclosed RM-055, which honestly is a unique concept.
Before daraxonrasib is even fully in the world, they’re building around resistance.
How it works:
• Most mutant RAS proteins are relatively resistant to GAP-mediated hydrolysis
• That helps keep RAS in the active state
• They’ve found a way to enhance that hydrolysis with RM-055
RM-055 can:
• restore hydrolysis in mutant RAS
• flatten daraxonrasib-resistant models
• generate activity even in RAS-amplified settings 👀
That’s a very smart way to think about this space.
Not just “here’s our inhibitor.”
More like: we already know resistance to our drug is coming, so let’s start building now.
That’s how we cure cancer, not more me-toos (if I hear about another new PD1 program I’m going to cry).
@OncoAlert @TheGutOncLab @Onco_Nexus
#CRCTrialsChat retweeted
Thank you, @AACR, for giving advocates a place to learn, ask questions, grow, and foster collaborations with scientists and other advocates. Your belief that we belong in these spaces has empowered us, helped us find our voices, and contributed in meaningful ways. #AACR26
Cancer survivor and patient advocate Jill Feldman receives the AACR Distinguished Patient Advocacy and Engagement Award during the Opening Ceremony at the AACR Annual Meeting 2026.
@jillfeldman4 #AACR26
#CRCTrialsChat retweeted
This is exciting!! I have always wanted to know the biomarker profile of folks without a cCR after TNT Perhaps combining biomarker directed therapies with SOC chemo as TNT is the next step to increase cCR rates and NOM for locally advanced rectal cancer Need #NCTN trials here!
Abstract CT011: Genomic HER2 amplification predicts for complete clinical response in a phase II study of induction tucatinib and trastuzumab combined with chemotherapy in locally advanced rectal adenocarcinoma (Presented at #AACR26 )
aacrjournals.org/cancerres/a…
This prospective single-arm study evaluated HER2-targeted 🧬 therapy in stage II–III HER2-positive rectal cancer. Patients received trastuzumab 🧪 and tucatinib with chemotherapy, achieving a 78% initial response and 75% overall response rate.
Complete clinical response occurred in select patients, particularly with strong HER2 expression, enabling non-operative management. With no metastatic recurrences at 26 months, results suggest HER2 amplification may predict response and support organ-preserving strategies in carefully selected patients.
@MikeFooteMD @AndreaCercek @LuisAntonioDiaz @KarunaMDPhD @RonaYaeger @DrGarciaAguilar @segaln @DrPaulRomesser
Ping faculty
@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen @NiuSanford @DaisukeKotani @DraMartinezLago @realbowtiedoc @p_ciracimd @GIMedOnc
#CRCTrialsChat retweeted
Mississippi has one of the highest colorectal cancer rates in the U.S.
Screening saves lives.
#ScreenAt45
#TowardsAHealthierMississippi
#CRCSM
#GetScreened!
#CRCTrialsChat retweeted
March is #ColorectalCancerAwareness Month 💙
When I was diagnosed with rectal cancer, everything changed overnight
Even with a science background, nothing prepares you emotionally for hearing the word “cancer.”
If you’re going through this, you are not alone
#CRCSM @colontown
#CRCTrialsChat retweeted
Fresh off an incredible #GI26. 💙 The COLONTOWN team was proud to present a poster on 5-FU Freedom (via pump self-disconnect), work that grew directly from patient-to-patient convos in our Community!
👉 If you self-disconnect your 5-FU pump, comment with your cancer center.
#CRCTrialsChat retweeted
Congratulations @VanitaNoronha and @TataMemorial team for asking really important questions about the right dose and duration of immunotherapy! We need to address over treatment !! @OncoAlert !
What if we’ve been overdosing immunotherapy all along?
In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! ascopubs.org/doi/10.1200/JCO… @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer
#CRCTrialsChat retweeted
What if we’ve been overdosing immunotherapy all along?
In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! ascopubs.org/doi/10.1200/JCO… @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer
#CRCTrialsChat retweeted
Incredibly grateful to Andy Chan for presenting our global #EOCRC Think Tank efforts at the #SU2CInnovationSummit. Grateful for the opportunity to highlight this collaborative, international work advancing #colorectalcancerresearch. #cancerresearch @SU2C
Learn more about our #GEOCRCTT: fightcolorectalcancer.org/wp…
#CRCTrialsChat retweeted
I’ve seen alot of posts recently about pancreatic cancer being “cured” in mice. Just a general reminder of something that is currently hung in my office:
#CRCTrialsChat retweeted
TODAY February 4, 2026: The 6th Annual OncoAlert Colloquium 🚨GI Malignancies
REGISTER👉 buff.ly/MjxFItr
GI Day 3 Feb 4, 2026
As ALWAYS ✅Patients Included
@BenWestphalen 🇩🇪
@GIMedOnc 🇺🇸
@Graokane 🇮🇪
@NiuSanford 🇺🇸
@realbowtiedoc 🇺🇸
@ARosen380 🇺🇸
@Erman_Akkus 🇹🇷
John Herrera Kok🇪🇸
Marco Inama 🇮🇹
@pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago
Our Partners
@ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg
#CRCTrialsChat retweeted
The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE
Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI
REGISTER HERE TO WATCH: buff.ly/FaS5Cb6
🚨 Practice-changing science in 2025: Upper GI Oncology 🚨
🔹 MATTERHORN🏔️ : Adding perioperative durvalumab to FLOT significantly improves outcomes in resectable gastric/GEJ cancer — marking immunotherapy’s entry into the curative-intent setting for fit, resectable disease.
🔹 DESTINY-Gastric04: Trastuzumab deruxtecan (T-DXd) clearly outperforms ramucirumab-based therapy in 2L HER2+ GEJ, confirming T-DXd as the preferred second-line standard after trastuzumab exposure. 🎯
🔹 HORIZON-GEA-01: Zanidatamab + chemo outperforms trastuzumab-based regimens in 1L HER2+ metastatic GEJ, establishing dual-HER2 blockade as the new frontline backbone.
2025 is reshaping the treatment paradigm in upper GI cancer — more targeted, more effective, and more personalized than ever. #UpperGI #Oncology #GastricCancer #HER2
@BenWestphalen 🇩🇪
@GIMedOnc 🇺🇸
@Graokane 🇮🇪
@NiuSanford 🇺🇸
@realbowtiedoc 🇺🇸
@ARosen380 🇺🇸
@Erman_Akkus 🇹🇷
John Herrera Kok🇳🇱
Marco Inama 🇮🇹
@pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago
